@article{9f631f51418c4884b970ee165ee551ca,
title = "Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease",
abstract = "COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.",
keywords = "COVID-19, Fullerene, Main protease, SARS-CoV-2",
author = "Daiki Katagishi and Daisuke Yasuda and Kyoko Takahashi and Shigeo Nakamura and Tadahiko Mashino and Tomoyuki Ohe",
note = "Funding Information: This work was supported by JST SPRING (Grant Number JPMJSP2123), the Keio University Doctorate Student Grant-in-Aid Program from Ushioda Memorial Fund, the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) from AMED (Grant Number JP21am0101089) and JSPS KAKENHI (Grant Number 21K18881). Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2023",
month = jan,
day = "15",
doi = "10.1016/j.bmcl.2022.129121",
language = "English",
volume = "80",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
}